101 related articles for article (PubMed ID: 20189046)
41. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
42. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
Wanic-Kossowska M
Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
[TBL] [Abstract][Full Text] [Related]
43. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.
Nissenson AR
Am J Kidney Dis; 2001 Dec; 38(6):1390-7. PubMed ID: 11728981
[TBL] [Abstract][Full Text] [Related]
44. ESAs in dialysis patients: are you a hedgehog or a fox?
Singh AK
J Am Soc Nephrol; 2010 Apr; 21(4):543-6. PubMed ID: 20357173
[No Abstract] [Full Text] [Related]
45. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
46. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
Rose S; Ali Y; Maffei B; Saidi P
Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
[No Abstract] [Full Text] [Related]
47. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
Kliger AS; Fishbane S; Finkelstein FO
Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
[TBL] [Abstract][Full Text] [Related]
48. Erythropoiesis-stimulating agents--time for a reevaluation.
Unger EF; Thompson AM; Blank MJ; Temple R
N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
[No Abstract] [Full Text] [Related]
49. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients - an eye-opener.
Binnani PG
Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1090. PubMed ID: 19861881
[No Abstract] [Full Text] [Related]
50. Darbepoetin alfa and chronic kidney disease.
Minnerup J; Schäbitz WR
N Engl J Med; 2010 Feb; 362(7):653-4; author reply 655. PubMed ID: 20187258
[No Abstract] [Full Text] [Related]
51. Treatment of anemia with epoetin in kidney transplant recipients.
Bren A; Arnol M; Kandus A; Varl J; Oblak M; Lindič J; Pajek J; Knap B; Kovač D; Mlinšek G; Buturović-Ponikvar J
Ther Apher Dial; 2011 Jun; 15(3):257-60. PubMed ID: 21624072
[TBL] [Abstract][Full Text] [Related]
52. Is anemia of cancer different from chemotherapy-induced anemia?
Steensma DP
J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523
[No Abstract] [Full Text] [Related]
53. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
54. Oxidative stress, renal anemia, and its therapies: is there a link?
Căpuşă C; Mircescu G
J Ren Nutr; 2010 Sep; 20(5 Suppl):S71-6. PubMed ID: 20797576
[TBL] [Abstract][Full Text] [Related]
55. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
56. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
57. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
Nakagawa T
Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
[No Abstract] [Full Text] [Related]
58. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
59. A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation.
Pankewycz O; Kulaylat M; Fagan L; Matthews B; Kohli R; Laftavi MR
Transplant Proc; 2010 Nov; 42(9):3537-41. PubMed ID: 21094811
[TBL] [Abstract][Full Text] [Related]
60. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con.
Himmelfarb J; Szczech LA
J Am Soc Nephrol; 2009 Jul; 20(7):1441-3. PubMed ID: 19579287
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
